Advancing the Fight Against Schistosomiasis with Rigorous Clinical Research
October 2024 – The VASA Project has reached a critical milestone in the development of its schistosomiasis vaccine, successfully completing enrollment for the Phase 1b clinical trial in Madagascar (MIVR) and Burkina Faso (GRAS). This marks a significant step forward in the mission to combat one of the most neglected tropical diseases affecting millions worldwide.
Phase 1b: A Vital Step in Vaccine Development
The Phase 1b study is designed to assess the safety, immunogenicity, and optimal dosage of the Sm-p80-based vaccine. Over the past two years, the project has achieved:
- Completion of enrollment in both clinical sites.
- Rigorous safety evaluations at predefined intervals.
- Ongoing immunogenicity assessments to determine vaccine effectiveness.
- Preparations for Last Subject Last Visit (LSLV), bringing us closer to trial completion.
Data collected from this phase will provide crucial insights into the vaccine’s potential and will inform the design of the upcoming Phase 2a trial, which will evaluate the vaccine’s efficacy in a larger population.
A Collaborative Effort Driving Innovation
The success of Phase 1b would not have been possible without the dedication of our research partners, clinical teams, and the communities involved in this vital work. We are grateful for the continued support of global health organizations, funding agencies, and regulatory partners who share our vision of a world free from schistosomiasis.
As we move closer to Phase 2a, we remain committed to scientific excellence, transparency, and collaboration, ensuring that this vaccine reaches those who need it most.
Stay connected with the VASA Project for more updates as we advance toward our next major milestone in schistosomiasis vaccine development.